Table 1.
Baseline characteristics of included studies
| Study | Country | Ethnicity | Sample size | Age (years) | Male (%) | Smoker (%) | Histology | Clinical stage | Time for T790M detection |
|---|---|---|---|---|---|---|---|---|---|
| Ishii et al36 | Japan | Japanese | 18 | 50–81 | 11.1 | 5.6 | Adenocarcinoma | Recurrent | Resistance developed |
| Thress et al18 | UK | Hesperian | 38 | NA | NA | NA | NSCLC | M0/M1a/M1b | Resistance developed |
| Wei et al42 | China | Chinese | 50a | 45–68 | 62.0 | 76.0 | Adenocarcinoma | IV | No resistance |
| Wang et al17 | China | Chinese | 108 | NA | 50.9 | 34.3 | NSCLC | IIIB/IV | Resistance developed |
| Takahama et al43 | Japan | Japanese | 260 | 36–90 | 30.0 | 27.3 | NSCLC | IIIB/IV/inoperable/recurrent | Resistance developed |
| Seki et al44 | Japan | Japanese | 35 | 47–74 | 40.0 | 31.4 | Adenocarcinoma | IV/recurrent | Resistance developed |
| Zheng et al24 | China | Chinese | 117 | NA | 39.3 | 24.8 | NSCLC | IIIB/IV/recurrent | Resistance developed |
| Sacher et al25 | USA | Hesperian | 180 | NA | 38.0 | NA | NSCLC | IIIB/IV/recurrent | Resistance developed |
| Yu et al22 | China | Chinese | 22 | 35–74 | 45.5 | NA | NSCLC | IIIB/IV | Resistance developed/no resistance |
| Suzawa et al23 | Japan | Japanese | 24a | 39–84 | 29.2 | 37.5 | NSCLC | NA | NA |
| Xu et al45 | China | Chinese | 20 | 37–76 | 50 | 30 | NSCLC | I–IV | NA |
Note:
a
Healthy volunteers in original study were not included here.
Abbreviations: NSCLC, nonsmall cell lung cancer; NA, not available.